10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
With the approval of Elunate (fruquintinib), China not only has a promising new option for colorectal cancer (CRC), a disease diagnosed in around 380,000 new Chinese people each year. 5 September 2018
A US-based former GlaxoSmithKline scientist has pled guilty to a charge of leaking trade secrets, two years after authorities filed a complaint. 5 September 2018
In a record 10 days after the drugs approval in Europe, NHS England has agreed that a groundbreaking new personalized CAR-T therapy can be made available to patients. 5 September 2018
Californian biotech firms Gilead Sciences and Trianni have entered into a license agreement to leverage the latter’s proprietary drug discovery platform. 5 September 2018
Shares in Californian biopharma MannKind Corporation closed 89% up on Tuesday as markets reacted to its licensing deal with biotech company United Therapeutics Corporation. 5 September 2018
Family-owned drugmaker Boehringer Ingelheim has agreed a broad collaboration with Beijing-based Tsinghua University to research and develop immunological therapies for infectious diseases. 5 September 2018
USA-based Merck has won priority review in the USA for a new supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab). 4 September 2018
Janssen has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for a drug that could offer something new in a therapy area that is pining for disruption. 4 September 2018
Though being vague on terms, and not naming the collaboration partner for a new licensing deal, UK life sciences firm OptiBiotix Health saw its shares, which had already risen 72% in the year to date, gain a further 6.5% to 105.97 pence by early afternoon trading today. 4 September 2018
Oxford University biotech spinout Evox Therapeutics has raised £35.5 million ($45.4 million) in a series B financing round, with new money from Google’s venture capital unit GV, and Cowen Healthcare Investments. 3 September 2018
Promore Pharma, a Swedish developer of therapeutic peptides, plans to expand the indications of its lead compound, the anti-adhesion and anti-scarring agent PXL01, to explore the feasibility of using the compound for the prevention of dermal scarring. 3 September 2018
Before joining Boston University to study biomedical engineering and chemistry, Mass Innovation Labs founder Amrit Chaudhuri was the youngest paid researcher at the MIT-affiliated Whitehead Institute for Biomedical Research, at age 15. 3 September 2018
French pharma major Sanofi has been granted EU approval to market Cablivi (caplacizumab) for episodes of a rare and life-threatening genetic disorder, acquired thrombotic thrombocytopenic purpura (aTTP). 3 September 2018
Danish biotech Genmab and its commercialization partner Janssen Biotech promise sales of Darzalex (daratumumab) in the front-line setting will start soon after the European Commission (EC) gave it the green light. 31 August 2018
A new study comparing Roche’s Lucentis (ranibizumab) with the firm’s own Avastin (bevacizumab) and Bayer's Eylea (aflibercept) supports Lucentis as a safe and effective therapy for the treatment of wet age-related macular degeneration (AMD). 31 August 2018
Some 12 years after the drug’s first US Food and Drug Administration (FDA) approval in leukemia, Bristol-Myers Squibb is still targeting new patients with Sprycel (dasatinib). 31 August 2018
In a disappointment for the company, Pfizer has scrapped the development of a potential Duchenne muscular dystrophy (DMD) candidate, a therapeutic area that the US pharma giant only entered in early 2015. 31 August 2018
Czech biotech firm SOTIO, part of the the privately-owned PPF Group, has completed the acquisition of Cytune Pharma, a firm developing IL-15 based therapies for the treatment of cancer, for an undisclosed sum. 30 August 2018
Weeks after a landmark approval in the USA, Alnylam Pharmaceuticals’ RNA interference (RNAi) therapeutic has been approved by the European Commission (EC). 30 August 2018
There was positive news today for Germany’s largest pharma company, with approval for its latest hemophilia A drug in the USA, which hopefully will provide a near term boost to its hemophilia portfolio. 30 August 2018